The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.
Chao-Hsien ChenHui-Chuan LinYa-Hui WangCheng-Yi WangYou Shuei LinChih-Cheng LaiPublished in: PloS one (2021)
Compared to a placebo, nintedanib was associated with a higher risk of adverse events, especially for diarrhea, nausea, vomiting and weight loss, but it was also associated with a lower risk of cough and dyspnea in IPF and fibrotic-ILD patients.
Keyphrases
- chemotherapy induced
- interstitial lung disease
- idiopathic pulmonary fibrosis
- systemic sclerosis
- rheumatoid arthritis
- end stage renal disease
- weight loss
- chronic kidney disease
- newly diagnosed
- prognostic factors
- systematic review
- ejection fraction
- bariatric surgery
- peritoneal dialysis
- body mass index
- type diabetes
- randomized controlled trial
- double blind